CONTEXT: Ovarian surface epithelial (OSE) cells express multiple nuclear hormone receptor genes, including those encoding thyroid hormone and estrogen receptors (TR and ER, respectively). Ovarian cancer is hormone-dependent, and epidemiological evidence links hyperthyroidism, inflammation of the ovarian surface, and increased risk of ovarian cancer. OBJECTIVE: The objective of this study was to assess T3 action on human OSE cells in vitro, asking 1) is there evidence for (pre)receptor control, 2) is T3 inflammatory, and 3) does T3 affect ER expression? DESIGN: Immunohistochemical analysis of fixed human ovaries and in vitro analysis of human OSE primary cell cultures were performed. PATIENTS: Twelve women aged 29-50 yr (median, 41 yr) undergoing elective gynecological surgery for nonmalignant conditions were studied. RESULTS: Messenger RNA transcripts for TRalpha1, TRalpha2, TRbeta1, and T3 activating deiodinase 2 and inactivating deiodinase 3 were present in primary OSE cell cultures by RT-PCR. TRalpha and TRbeta proteins were also localized to intact OSE by immunohistochemistry. Treatment of OSE cell cultures for 24 h with T3 caused dose-dependent mRNA expression of inflammation-associated genes: cyclooxygenase-2, matrix metalloproteinase-9, and 11betahydroxysteroid dehydrogenase type 1, determined by quantitative RT-PCR. Finally, treatment with T3 dose dependently stimulated ERalpha mRNA expression without affecting ERbeta1 or ERbeta2. CONCLUSION: The ovarian surface is a potential T3 target. T3 exerts direct inflammatory effects on OSE cell function in vitro. OSE cell responses to T3 include increased expression of ERalpha mRNA, which encodes the ER isoform most strongly associated with ovarian cancer. This could help explain suggested epidemiological links between hyperthyroidism and ovarian cancer.
CONTEXT: Ovarian surface epithelial (OSE) cells express multiple nuclear hormone receptor genes, including those encoding thyroid hormone and estrogen receptors (TR and ER, respectively). Ovarian cancer is hormone-dependent, and epidemiological evidence links hyperthyroidism, inflammation of the ovarian surface, and increased risk of ovarian cancer. OBJECTIVE: The objective of this study was to assess T3 action on human OSE cells in vitro, asking 1) is there evidence for (pre)receptor control, 2) is T3 inflammatory, and 3) does T3 affect ER expression? DESIGN: Immunohistochemical analysis of fixed human ovaries and in vitro analysis of human OSE primary cell cultures were performed. PATIENTS: Twelve women aged 29-50 yr (median, 41 yr) undergoing elective gynecological surgery for nonmalignant conditions were studied. RESULTS: Messenger RNA transcripts for TRalpha1, TRalpha2, TRbeta1, and T3 activating deiodinase 2 and inactivating deiodinase 3 were present in primary OSE cell cultures by RT-PCR. TRalpha and TRbeta proteins were also localized to intact OSE by immunohistochemistry. Treatment of OSE cell cultures for 24 h with T3 caused dose-dependent mRNA expression of inflammation-associated genes: cyclooxygenase-2, matrix metalloproteinase-9, and 11betahydroxysteroid dehydrogenase type 1, determined by quantitative RT-PCR. Finally, treatment with T3 dose dependently stimulated ERalpha mRNA expression without affecting ERbeta1 or ERbeta2. CONCLUSION: The ovarian surface is a potential T3 target. T3 exerts direct inflammatory effects on OSE cell function in vitro. OSE cell responses to T3 include increased expression of ERalpha mRNA, which encodes the ER isoform most strongly associated with ovarian cancer. This could help explain suggested epidemiological links between hyperthyroidism and ovarian cancer.
Authors: Paola B Navas; Analía L Redondo; F Darío Cuello-Carrión; Laura M Vargas Roig; Susana R Valdez; Graciela A Jahn; María B Hapon Journal: Thyroid Date: 2014-06 Impact factor: 6.568
Authors: Tim I M Korevaar; Lidia Mínguez-Alarcón; Carmen Messerlian; Ralph A de Poortere; Paige L Williams; Maarten A Broeren; Russ Hauser; Irene C Souter Journal: Thyroid Date: 2018-08-14 Impact factor: 6.568
Authors: Ji Hee Ha; Jeremy D Ward; Lakshmi Varadarajalu; Sang Geon Kim; Danny N Dhanasekaran Journal: Cell Signal Date: 2013-09-19 Impact factor: 4.315
Authors: E Shinderman-Maman; K Cohen; C Weingarten; D Nabriski; O Twito; L Baraf; A Hercbergs; P J Davis; H Werner; M Ellis; O Ashur-Fabian Journal: Oncogene Date: 2015-07-13 Impact factor: 9.867
Authors: R Canipari; C Mangialardo; V Di Paolo; F Alfei; S Ucci; V Russi; M G Santaguida; C Virili; M Segni; S Misiti; M Centanni; C Verga Falzacappa Journal: J Endocrinol Invest Date: 2018-06-22 Impact factor: 4.256
Authors: Anatte E Karmon; Eden R Cardozo; Irene Souter; Julie Gold; John C Petrozza; Aaron K Styer Journal: J Assist Reprod Genet Date: 2016-02-04 Impact factor: 3.412
Authors: Jae H Kang; Angela S Kueck; Richard Stevens; Gary Curhan; Immaculata De Vivo; Bernard Rosner; Erik Alexander; Shelley S Tworoger Journal: Obstet Gynecol Int Date: 2013-07-15